

Future of Cardiovascular Diagnostics: Impact of Technological Advances on Growth Opportunities and Market Outlook

Introduction

The report analyzes a variety of cardiac biomarkers currently on the market, including those used to determine cholesterol and lipoprotein levels, cardiac necrosis, thrombosis, inflammation and genetic variants. Furthermore, a large number of biomarkers are currently under evaluation, and if successful, may provide cardiologists with a more comprehensive assessment of cardiovascular risk and prognosis.

Scope

- Analyzes key IVD and imaging technologies, and their applications for early diagnosis, treatment and patient monitoring in CVD.
- Assesses current approaches being adopted by the leading IVD and emerging market entrants.
- Profiles leading companies developing novel technologies for IVD and diagnostic imaging.
- Analyses potential of products and technologies for improving diagnosis and guiding treatment decisions earlier during the course of CVD.
- Reviews benefits associated with different approaches to IVD and diagnostic imaging.

Research and analysis highlights

Increasingly, IVD testing is being used by cardiologists in conjunction with diagnostic imaging to stratify patient risk, improve diagnosis, minimize the use of invasive procedures and improve patient management.

Several tests are now available that can identify asymptomatic patients that are at high risk of CV disease, allowing for early dietary and lifestyle interventions and the prescription of preventative medicine if necessary.

Extensive research indicates that the application of IVD and diagnostic imaging in cardiovascular disease may lead to significant reductions in healthcare costs by increasing the speed of diagnosis, avoiding the need for expensive treatments and reducing mortality rates through early screening programs.

Key reasons to purchase this research

- Discover the reasons for the increasing usage of IVD and diagnostic imaging modalities in recent years.
- Identify the technologies at the forefront of cardiovascular IVD and diagnostic imaging.
- Assess the IVD and healthcare industry's responses to the demands of cardiologists and radiologists.
- Examine the strategies that the leading IVD and healthcare companies use in order to remain ahead in the CV diagnostics field.

Table of Contents

Cardiovascular Diagnostics

Executive Summary 10

Cardiovascular disease & diagnostics 10

Current cardiac diagnostic modalities 11

Novel cardiac diagnostic modalities 12

The market, trends & future directions 13

Chapter 1 Cardiovascular disease & diagnostics 16

Introduction 17

Cardiovascular disease 20

Cardiovascular risk factors 23

Diagnosis of cardiovascular diseases 25

Cardiovascular screening 25

Conclusions on CVD diagnosis and screening 27

Cardiovascular diagnostics 28

Cardiovascular in vitro diagnostics: biomarkers and tests 28

Cholesterol testing 28

Lipoprotein & apolipoprotein profiling 30

Cholesterol guidelines 31

Case study: Atherotech VAP technology 32

Cardiac biomarkers 34

In vivo cardiovascular diagnostics: options & applications 36

Diagnostic imaging for coronary artery disease 38

Diagnostic imaging for stroke 40

Diagnostic imaging for pulmonary embolism 40

Conclusions on diagnostic imaging modalities 41

Report outline 41

Chapter 2 Current cardiac diagnostic modalities 44

Introduction 45

Coronary artery disease diagnostic tests 46

In vitro diagnosis of CAD 46

In vivo diagnosis of CAD 49

Conclusions on diagnostic tests for CAD 54

Acute coronary syndromes diagnostics 55

In vitro diagnosis for ACS 56

In vivo diagnosis of ACS 59

Conclusions on diagnostic tests for heart attack patients 62

Heart failure 62

In vitro diagnosis of heart failure 64

In vivo diagnosis of heart failure 65

Conclusion on diagnostic tests for CHF 68

Stroke 68

In vivo diagnosis of stroke 69
In vitro diagnosis of stroke 71
Conclusion on diagnostic tests for stroke 73
Deep vein thrombosis & pulmonary embolism 73
In vitro tests for PE 74
In vivo diagnosis of PE 76
Conclusion on diagnostic tests for DVT & PE 78
Coagulation diagnostics 78
Genotyping in cardiovascular disease 80
Cytochrome P450 80
ApoE genotyping 80
Cardiac channelopathies 81
Thrombophilia genotyping 81
Overall conclusions 82
Chapter 3 Novel cardiac diagnostic modalities 86
Introduction 87
Challenges 87
Tough economic environment 87
Healthcare coverage & regulation 89
Payment & reimbursement 89
Emerging markets 90
Conclusions on challenges 92
Opportunities 92
New cardiac biomarkers 93
Pharmacogenomics 99
Genetic biomarkers to guide treatment decisions 100
Genetic biomarkers of cardiovascular risk 101
Point of care testing 104
Novel imaging agents 107
Cardiovascular molecular imaging 109
Novel imaging modalities 110
Case study: Magnetic Particle Imaging (Philips Healthcare) 110
Hybrid imaging systems 111
PET-MRI 112
PET-CT 112
SPECT-CT 113
Computer assisted diagnosis & artificial intelligence 113
Conclusions 114
Overall conclusions 114
Chapter 4 The market, trends & future directions 118
Market analysis 119
The IVD market 119
The cardiovascular IVD market 123
The diagnostic imaging market 128

Leading IVD & imaging companies	132
Abbott, Illinois, US	132
Beckman Coulter, California, US	132
Becton Dickinson & Company, NJ, US	133
bioMérieux, Marcy L'Etoile, France	133
GE Healthcare, New York, US	134
Hitachi Medical Corporation, Tokyo, Japan	135
Inverness Medical Innovations, Inc., MA, US	135
Johnson & Johnson, NJ, US	136
Philips Healthcare, Amsterdam, the Netherlands	137
Roche, Basel, Switzerland	137
Siemens Healthcare, Berlin & Munich, Germany	138
Toshiba Medical Systems Corporation, Tokyo, Japan	139
M&A activity	140
Recent collaborations & agreements	145
Recent product launches & trends	148
Cardiovascular in vitro diagnostics	148
Cardiovascular diagnostic imaging	149
Future directions	152
Summary & overall conclusions	153
Chapter 5 Appendices	158
Primary research methodology	158
Glossary	159
Acknowledgements	163
Index	164
Bibliography & Endnotes	166
List of Figures	
Figure 1.1: Cardiovascular diagnostic platforms	18
Figure 1.2: CVD – breakdown of deaths in the US (2006)	22
Figure 1.3: Increased use of medicine reduces the risk of death after stroke and heart attack	26
Figure 1.4: Increased use of medicine reduces the risk of death after stroke and heart attack	27
Figure 1.5: VAP test – treatment guideline	33
Figure 2.6: Conventional coronary angiography	50
Figure 2.7: EBCT angiogram of heart and pulmonary arteries	52
Figure 2.8: Principals of MSCT angiography scan of heart and pulmonary arteries	53
Figure 2.9: Diagnosis & risk stratification of ACS patients	56
Figure 2.10: Profile of cardiac necrosis markers after acute MI	57
Figure 2.11: Typical electrocardiogram from a healthy adult heart	59
Figure 2.12: Typical electrogram observed during ACS patient with US/NSTEMI	60
Figure 2.13: Typical electrogram observed during ACS patient with STEMI	61
Figure 2.14: Diagnosis & risk stratification of HF patients	63
Figure 2.15: Echocardiogram	66

Figure 2.16: MUGA scan of the heart 67

Figure 2.17: Doppler Ultrasound in a) normal & b) stroke 69

Figure 2.18: MRI scan of brain following a stroke 70

Figure 2.19: Commercial MRI Units 71

Figure 2.20: Increased risk of stroke with elevated Lp-PLA2 (ARIC Study) 72

Figure 2.21: Roche's PoC CARDIAC D-Dimer test 75

Figure 2.22: Ventilation-perfusion scan for detecting PEs 76

Figure 2.23: Contrast enhanced CT image of PE 77

Figure 3.24: Global Population (2008) 91

Figure 3.25: Schematic of MPI technology 111

Figure 4.26: The IVD market – geographic split (2008) 119

Figure 4.27: The IVD market – segments (2008) 120

Figure 4.28: The IVD market – market leaders (2008) 121

Figure 4.29: Cardiovascular Diagnostics – Market Segments (2008) 124

Figure 4.30: Leading diagnostic imaging companies (2008) 129

Figure 4.31: Leading diagnostic imaging – market segments (2008) 130

List of Tables

Table 1.1: CVD – conditions & associated risk factors 20

Table 1.2: CVD – conditions & associated risk factors (continued) 21

Table 1.3: Uncontrollable cardiovascular risk factors 23

Table 1.4: Protective cardiovascular risk factors 23

Table 1.5: Controllable / treatable cardiovascular risk factors 24

Table 1.6: ATPIII Classification of TC, LDL-C & HDL-C 32

Table 1.7: Commercially available cardiovascular diagnostics to assess acute coronary syndromes 34

Table 1.8: Commercially available diagnostics to assess cardiovascular risk, stroke & thrombosis 35

Table 1.9: Anatomical - In vivo imaging modalities 36

Table 1.10: Functional - In vivo imaging modalities 37

Table 1.11: Advantages & disadvantages of cardiac imaging modalities 38

Table 1.12: In vivo imaging tests to assess cardiac anatomy & function 39

Table 2.13: Diagnostic tests - CAD 46

Table 2.14: Diagnostics for ACS 55

Table 2.15: Diagnostic tests for heart failure 64

Table 2.16: Properties of BNP 64

Table 2.17: Leading diagnostics for stroke 68

Table 2.18: Leading thrombotic diagnostic tests 74

Table 3.19: COACH trial data on Galectin-3 95

Table 3.20: Commercially available POC cardiac tests 106

Table 4.21: Medical Device Manufacturers & Suppliers in IVD 122

Table 4.22: Medical Device Manufacturers & Suppliers in IVD (continued) 123

Table 4.23: Cardiovascular focused IVD companies 126

Table 4.24 Cardiovascular focused IVD companies (continued): 127

Table 4.25: Medical device manufacturers & suppliers in imaging 131

Table 4.26: Recent M&A activity in the cardiovascular diagnostic arena	142
Table 4.27: Recent M&A activity in the cardiovascular diagnostic arena (continued)	143
Table 4.28: Recent M&A activity in the cardiovascular diagnostic arena (continued)	144
Table 4.29: Recent collaborations in the cardiovascular arena	146
Table 4.30: Recent collaborations in the cardiovascular diagnostic arena (continued)	147
Table 4.31: Recent product launches in cardiovascular IVDs	148
Table 4.32: Recent product launches in diagnostic imaging	151